COX-3: Just another COX or the solitary elusive target of paracetamol?

Lancet

Volumn 361, Issue 9362, 2003, Pages 981-982

  Schwab, Jan M ^a   Schluesener, Hermann J ^a   Laufer, Stefan ^b  

^a Medical School   (Germany)

^b UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANALGESIC AGENT; BRAIN PROTEIN; CYCLOOXYGENASE 2 INHIBITOR; CYCLOOXYGENASE 3; DICLOFENAC; IBUPROFEN; INDOMETACIN; KETOPROFEN; NAPROXEN; PARACETAMOL; PROSTAGLANDIN DERIVATIVE; THROMBOXANE DERIVATIVE; UNCLASSIFIED DRUG;

ALTERNATIVE RNA SPLICING; ANALGESIA; CARDIOVASCULAR DISEASE; DIGESTIVE SYSTEM ULCER; DRUG ACTIVITY; DRUG MECHANISM; DRUG SAFETY; DRUG TARGETING; ENZYME INACTIVATION; ENZYME INHIBITION; ENZYME STRUCTURE; HUMAN; IC 50; KNOCKOUT GENE; NEPHROTOXICITY; NOTE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FOLDING; PROTEIN FUNCTION; PROTEIN LOCALIZATION; THROMBOCYTE AGGREGATION INHIBITION; TISSUE DISTRIBUTION;

EID: 0037460805     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(03)12841-3     Document Type: Note

References (13)

1. Vane J.R. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nat New Biol. 23:1971;232-235.
2. Crofford L.J. COX-1 and COX-2 tissue expression: implications and predictions. J Rheumatol. 24:(suppl 49):1997;15-19.
3. Laulederkind S.J., Thompson-Jaeger S., Goorha S., et al. Both constitutive and inducible prostaglandin H synthase affect dermal wound healing in mice. Lab Invest. 82:2002;919-927.
4. Bombardier C., Laine L., Reicin A., et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis: VIGOR Study Group. N Engl J Med. 343:2000;1520-1528.
5. Willoughby D.A., Moore A.R., Colville-Nash P.R. COX-1, COX-2, and COX-3 and the future treatment of chronic inflammatory disease. Lancet. 355:2000;646-668.
6. Botting R.M. Mechanism of action of acetaminophen: is there a cyclooxygenase 3? Clin Infect Dis. 31:(suppl 5):2000;S202-S210.
7. Chandrasekharan N.V., Dai H., Roos K.L., et al. COX-3, a cyclooxygenase-1 variant inhibited by acetaminophen and other analgesic/antipyretic drugs: cloning, structure, and expression. Proc Natl Acad Sci USA. 99:2002;13926-13931.
8. Plant M.H., Laneuville O. Characterization of a novel transcript of prostaglandin endoperoxide H synthase 1 with a tissue-specific profile of expression. Biochem J. 344:1999;677-685.
9. Hla T. Molecular characterization of the 5·2 KB isoform of the human cyclooxygenase-1 transcript. Prostaglandins. 51:1996;81-85.
10. Langenbach R., Morham S.G., Tiano H.F., et al. Prostaglandin synthase 1 gene disruption in mice reduces arachidonic acid-induced inflammation and indomethacin-induced gastric ulceration. Cell. 83:1995;483-492.
11. Warner T.D., Mitchell J.A. Cyclooxygenase-3 (COX-3): filling in the gaps toward a COX continuum? Proc Natl Acad Sci USA. 99:2002;13371-13373.
12. Mazario J., Gaitan G., Herrero J.F. Cyclooxygenase-1 vs cyclooxygenase-2 inhibitors in the induction of antinociception in rodent withdrawal reflexes. Neuropharmacology. 40:2001;937-946.
13. USFood and Drug Administration Arthritis Advising Committee, Dec 1, 1997: http://www.fda.gov/ohrms/dockets/ac/98/slides/3480s1d.pdf (accessed on March 17, 2003).